Abstract:Thalidomide was originally developed in 1954 as a sedative that was commonly used to ameliorate morning sickness. However, thalidomide exposure during the first trimester of pregnancy caused multiple birth defects (e.g. phocomelia and amelia), affecting ≈ 10,000 children worldwide in the late 1950s and early 1960s. Thalidomide is now recognized as a clinically effective, albeit strictly restricted, drug for the treatment of leprosy and multiple myeloma. Investigators have studied thalidomide teratogenicity for half a century, proposing over 30 hypotheses to account for its actions. Among these, the anti-angiogenesis and oxidative stress models have gained widespread support. Nonetheless, the precise molecular mechanisms and direct targets of thalidomide have not heretofore been elucidated. We developed ferrite-glycidyl methacrylate beads that enable magnetic separation and efficient purification of ligand-binding molecules; the beads were recently employed to identify cereblon as a primary target of thalidomide. Cereblon forms an E3 ubiquitin ligase complex with DDB1, Cul4A, and Roc1, which is important for the expression of fibroblast growth factor 8, an essential regulator of limb development. Expression of a drug binding-deficient mutant of cereblon suppressed thalidomide-induced effects in zebrafish and chicks. This suggests that thalidomide downregulates fibroblast growth factor 8 expression and induces limb malformation by binding to wild-type cereblon, inhibiting the function of the associated E3 ubiquitin ligase. The present review summarizes the teratogenicity of thalidomide, including existing models for its mode of action, and discusses the identification of cereblon as a key molecule for deciphering the longstanding mystery of thalidomide teratogenicity.

Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN

Crystal structure of the SALL4–pomalidomide–cereblon–DDB1 complex

The molecular mechanism of thalidomide analogs in hematologic malignancies

Thalidomide Inhibits Human iPSC Mesendoderm Differentiation by Modulating CRBN-dependent Degradation of SALL4

Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells

Structural basis of lenalidomide-induced CK1α degradation by the CRL4CRBN ubiquitin ligase

Molecular mechanisms of cereblon-based drugs

The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins.

Deciphering the mystery of thalidomide teratogenicity

Direct-to-biology, automated, nano-scale synthesis, and phenotypic screening-enabled E3 ligase modulator discovery

SALL4 mediates teratogenicity as a thalidomide-dependent cereblon substrate

How Thalidomide Works Against Cancer

Orthogonal IMiD-Degron Pairs Induce Selective Protein Degradation in Cells

Strengthening molecular glues: design strategies for improving thalidomide analogs as cereblon effectors and anticancer agents

Discovery of thalidomide-based PROTAC small molecules as the highly efficient SHP2 degraders

Possible New Candidates Involved to Thalidomide-Related Limbs and Cardiac Defects: A Systems Biology Approach

The E3 ligase adapter cereblon targets the C-terminal cyclic imide degron

Cereblon Modulators Target ZBTB16 and Its Oncogenic Fusion Partners for Degradation Via Distinct Structural Degrons.

UBE2G1 Governs the Destruction of Cereblon Neomorphic Substrates

Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide

A Cereblon Modulator (CC-220) with Improved Degradation of Ikaros and Aiolos.